New Delhi, India — 01/12/2018 — Respiratory Syncytial Virus (RSV) is the main viral cause of respiratory tract infection in newborn infants as well as some elderly and high-risk adults with chronic pulmonary disease and are severely immune compromised. Generally, infection is restricted to the upper respiratory tract and not associated with long-term pathology, but progression to a more severe lower respiratory tract infection is frequent. Currently, RSV is considered as the main reason for causing acute lower respiratory infection (ALRI) and a major cause of hospital admissions and death in young children.

According to the latest report of DelveInsight, “Respiratory Syncytial Virus Infections – Market Insights, Epidemiology and Market Forecast-2025”, approximately 0.5% to 2.0% of children are hospitalized with lower respiratory tract disease, of which 50% to 90% have bronchiolitis and 5% to 40% have pneumonia. In the US, this problem led to approximately 57,000 hospitalizations of Children younger than 5 Years Old. On the other hand, in Europe, it is the cause of about 45% of the hospital admissions below 2 years. In Japan, the annual rate of hospitalization is around 59 per 1,000 children under the age of 12 years. The total number of RSV cases is expected to increase during the period of 2015-2025.

As per the estimations market for preventive therapies to treat RSV Infections will experience modest annual growth over the period of 2017-2025. Synagis (MedImmune), Virazole (Valeant Pharmaceuticals) and RespiGam (MedImmune) are the approved drugs for treating RSV targeting infants. Synagis is the only immunoprophylaxis approved for pediatric patients. Some emerging therapies for fighting against RSV are Presatovir (Gilead Sciences), RRV521 (ReViral), and RSV F vaccine (Novavax). Emerging Drugs are expected to drive the future RSV market. The market has some unmet needs like the absence of any targeted drug for adults, which is expected to drive the research activities.

The latest report has covered a detailed description of Disease Diagnostics, pathophysiology, risk factors and other details regarding RSV. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of RSV is provided covering the 7MM to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the major market scenario. Complete details about the currently marketed drugs to understand the present market competition and market performance of each and every competitor out there. The report has covered all the unmet needs in the current domain to understand the areas of improvement. Details about all the possible market drivers and barriers are also provided to better understand to plan the strategies accordingly.

Reasons to buy:
– The report will help in developing business strategies by understanding trends shaping and driving the RSV market.
– To understand the future market competition in the RSV market and Insight reviews of the key market drivers and barriers.
– Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
– In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
– MedImmune
– Valeant Pharmaceuticals
– Gilead Sciences
– ReViral
– Novavax
And many others……………..

Table of Contents:

1. Report Introduction

2. Respiratory Syncytial Virus Market Overview at a Glance

2.1. 7 Major Market Size of Respiratory Syncytial Virus in 2016

2.2. 7 Major Market Size of Respiratory Syncytial Virus in 2025

3. Disease Background and Overview: Respiratory Syncytial Virus

3.1. Introduction

3.2. Causes

3.3. Pathophysiology

3.4. Symptoms

3.5. Risk Factor

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Assumptions and Caveats

5. Respiratory Syncytial Virus Geography wise Prevalent Cases

5.1. 7MM Prevalent Cases of Respiratory Syncytial Virus in 2016

5.2. 7MM Prevalent Cases of Respiratory Syncytial Virus in 2025

6. United States

6.1. Assumptions and Rationale

6.2. Prevalent Cases of Respiratory Syncytial Virus in United States (2015-2025)

7. Europe

8. Germany

8.1. Assumptions and Rationale

8.2. Prevalent Cases of Respiratory Syncytial Virus in Germany (2015-2025)

9. Italy

9.1. Assumptions and Rationale

9.2. Prevalent Cases of Respiratory Syncytial Virus in Italy (2015-2025)

10. Spain

10.1. Assumptions and Rationale

10.2. Prevalent Cases of Respiratory Syncytial Virus in Spain (2015-2025)

11. France

11.1. Assumptions and Rationale

11.2. Prevalent Cases of Respiratory Syncytial Virus in France (2015-2025)

12. United Kingdom

12.1. Assumptions and Rationale

12.2. Prevalent Cases of Respiratory Syncytial Virus in United Kingdom (2015-2025)

13. Japan

13.1. Assumptions and Rationale

13.2. Prevalent Cases of Respiratory Syncytial Virus in Japan (2015-2025)

14. Treatment Algorithm

14.1. United States

14.2. Japan

14.3. Europe

15. Marketed drugs

15.1. List of Marketed Drugs

16. Synagis (palivizumab): MedImmune

16.1. Mechanism of action

16.2. Regulatory Milestones

16.3. Advantages and disadvantages

16.4. Safety and efficacy

16.5. Side effects

16.6. Product profile

17. Emerging Therapies

17.1. Key Cross Competition

18. RSV F vaccine: Novavax, Inc.

18.1. Regulatory Milestones

18.2. Clinical Development

18.3. Product Profile

18.4. Clinical Pipeline Activity

18.4.1. Ongoing Trials Information

18.4.2. Clinical Trial by Phase

19. Presatovir: Gilead Sciences

19.1. Regulatory Milestones

19.2. Clinical Development

19.3. Product Profile

19.4. Clinical Pipeline Activity

19.4.1. Ongoing Trials Information

19.4.2. Clinical Trial by Phase

20. RRV521: ReViral Ltd

20.1. Regulatory Milestones

20.2. Clinical Development

20.3. Product Profile

20.4. Clinical Pipeline Activity

20.4.1. Ongoing Trials Information

20.4.2. Clinical Trial by Phase

21. Respiratory Syncytial Virus Market Size

21.1. Key Findings

21.2. Market Size: Assumptions and Forecast Parameters

22. Total 7MM Respiratory Syncytial Virus Market Analysis

23. Overview of Total Respiratory Syncytial Virus Market (2015-2025)

24. 7MM Respiratory Syncytial Virus : Market Analysis

24.1. Overview on Total Respiratory Syncytial Virus (2016)

24.2. Overview on Total Respiratory Syncytial Virus (2025)

25. 7MM Respiratory Syncytial Virus : Country-Wise Market Analysis

26. United States Market Size

26.1. Market Analysis

26.2. Emerging therapies analysis: impact on the market

27. Germany Market Size

27.1. Market Analysis

27.2. Emerging therapies analysis: impact on the market

28. France Market Size

28.1. Market Analysis

28.2. Emerging therapies analysis: impact on the market

29. United Kingdom Market Size

29.1. Market Analysis

29.2. Emerging therapies analysis: impact on the market

30. Spain Market Size

30.1. Market Analysis

30.2. Emerging therapies analysis: impact on the market

31. Italy Market Size

31.1. Market Analysis

31.2. Emerging therapies analysis: impact on the market

32. Japan Market Size

32.1. Market Analysis

32.2. Emerging therapies analysis: impact on the market

33. Market Drivers

34. Market Barriers

35. Report Methodology

36. Consulting Services

37. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making the long-lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results and equipping our clients to grow and lead.

Contact Us:
[email protected]
Tel: +91-9650213330
USA: +1(919)321-6187
website: https://www.delveinsight.com/

Powered by WPeMatico